EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Theratyping of the ultra-rare CFTR variant p.Phe1078Ser: functional correction by CFTR modulators in human bronchial epithelial CFBE cells

Louise Damy, Mael Estivalezes, Isabelle Callebaut, Nada El Makhzen, Sandra Mirval, Matthieu Regnacq, Christine Barrault, Hugues Abriel, Frédéric Becq

Frontiers in Pharmacology · 19.11.2026 · 17

DOI: 10.3389/fphar.2026.2007119 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Frontiers in Pharmacology, online erschienen am 19.11.2026. Verfasst von Louise Damy und 8 weiteren Autor:innen. Die Arbeit nennt 28 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Association Vaincre la Mucoviscidose.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

CFTR c.3233 T>C (p.(Phe1078Ser); F1078S) is an ultra-rare missense variant for which clinical and functional data are very limited. As theratyping is an important experimental component of precision theranostics in cystic fibrosis (CF), we investigated the molecular and functional consequences of F1078S and its responsiveness to CFTR modulators.

Methods

F1078S-CFTR was transiently expressed in human bronchial epithelial CFBE41o − cells using a GFP-tagged CFTR construct. CFTR protein processing and biosynthesis were assessed by Western blotting, while channel function was evaluated by Ussing chamber recordings. The effects of elexacaftor and vanzacaftor, each combined with tezacaftor were investigated. F1078 was mapped on the three-dimensional (3D) structure of human CFTR.

Results

F1078 is located at the ICL1/ICL4 interface, near the “pocket” left vacant by F508 in patients with F508del (ICL4/NBD1 interface). F1078S-CFTR exhibited defective protein processing, as evidenced by the absence of the mature C-band, and showed no detectable CFTR channel function. Treatment of F1078S-expressing CFBE41o − cells with elexacaftor/tezacaftor or vanzacaftor/tezacaftor restored CFTR protein processing and rescued channel function.

Conclusion

F1078S located in a critical region for folding and assembly, exhibits a CFTR processing/trafficking defect consistent with a class II molecular phenotype, together with impaired channel function. Both defects were rescued by elexacaftor/tezacaftor and vanzacaftor/tezacaftor, providing functional evidence of CFTR modulator responsiveness for this ultra-rare variant. These findings highlight the potential of theratyping to inform individualized therapeutic strategies for patients carrying rare CFTR variants.

Förderung

  • Association Vaincre la Mucoviscidose

Zitieren

APA

Damy, L., Estivalezes, M., Callebaut, I., Makhzen, N. E., Mirval, S., Regnacq, M., Barrault, C., Abriel, H., & Becq, F. (2026). Theratyping of the ultra-rare CFTR variant p.Phe1078Ser: functional correction by CFTR modulators in human bronchial epithelial CFBE cells. Frontiers in Pharmacology, 17. https://doi.org/10.3389/fphar.2026.2007119

Vancouver

Damy L, Estivalezes M, Callebaut I, Makhzen NE, Mirval S, Regnacq M, et al. Theratyping of the ultra-rare CFTR variant p.Phe1078Ser: functional correction by CFTR modulators in human bronchial epithelial CFBE cells. Frontiers in Pharmacology. 2026;17. doi:10.3389/fphar.2026.2007119

BibTeX
@article{Damy2026,
  author = {Damy, Louise and Estivalezes, Mael and Callebaut, Isabelle and Makhzen, Nada El and Mirval, Sandra and Regnacq, Matthieu and Barrault, Christine and Abriel, Hugues and Becq, Frédéric},
  title = {Theratyping of the ultra-rare CFTR variant p.Phe1078Ser: functional correction by CFTR modulators in human bronchial epithelial CFBE cells},
  journal = {Frontiers in Pharmacology},
  year = {2026},
  volume = {17},
  doi = {10.3389/fphar.2026.2007119}
}
Kostenlos starten →